{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:29:24Z","timestamp":1776709764371,"version":"3.51.2"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of adoptive cellular immunotherapy targeting CD19 in its most advanced form. Up to 30% of infused patients achieve long-term survival, meaning that 70% of patients still fail to respond or relapse after therapy. This review will address the unresolved issues relating to responders\u2019 characterization, relapse prediction, and prevention, CAR T-cell construct optimization, rational combination with other therapies and treatment toxicity, focusing on the management of relapsed\/refractory lymphoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Many new antigenic targets are currently investigated and raise the hope of broader successes. However, literature data report that treatment failure is not only related to CAR T construct and infusion but is also due to hostile tumor microenvironment and poor interaction with the host effector cells. Further research should not only target CAR T structure, toxicity and associated therapies, but also tumor-related and host-related microenvironment interactions that lead to treatment failure in relapsed\/refractory lymphoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Poor persistence of CAR T and loss of CD19 antigen are well established mechanisms of relapse in Acute Lymphoblastic Leukemia (ALL). A fourth generation of CAR T construct is currently investigated to overcome this issue. In non-Hodgkin lymphoma, mechanisms of treatment failure remain poorly understood but tumor and host microenvironment are undoubtedly involved and should be further investigated. A deeper understanding of CAR T-cell therapy failure in individuals will help personalize CAR T-cell therapy in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000671","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T17:57:10Z","timestamp":1597168630000},"page":"434-441","source":"Crossref","is-referenced-by-count":6,"title":["Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions"],"prefix":"10.1097","volume":"32","author":[{"given":"Adriano","family":"Salaroli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Spilleboudt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lewalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/pharmaceutics12020194","article-title":"Chimeric antigen receptor-T-cell therapy for B-cell haematological malignancies: an update of the pivotal clinical trial data","volume":"12","author":"Roex","year":"2020","journal-title":"Pharmaceutics"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-cell product performance in haematological malignancies before and after marketing authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced antitumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signalling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"10679","DOI":"10.1073\/pnas.97.20.10679","article-title":"Breaking the affinity ceiling for antibodies and T cell receptors","volume":"97","author":"Foote","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J Immunol"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","article-title":"Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell Attack","volume":"24","author":"Hombach","year":"2016","journal-title":"Mol Ther"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR t-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"R22-20230901","first-page":"3894","article-title":"Modulation of CD22 antigen density improves efficacy of CD22 chimeric antigen receptor (CAR) T cells against CD22lo B-lineage leukemia and lymphoma","volume":"130","author":"Ramakrishna","year":"2017","journal-title":"Blood"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","article-title":"Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis","volume":"105","author":"Dotti","year":"2005","journal-title":"Blood"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI121491","article-title":"T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy","volume":"129","author":"Yamamoto","year":"2019","journal-title":"J Clin Invest"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chimeric antigen receptor T cell efficacy in solid tumors","volume":"26","author":"Fuc\u00e1","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-020-0706-6","article-title":"Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"21","author":"Badar","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"18","author":"Lytle","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.4049\/jimmunol.1901213","article-title":"Metformin enhances the antitumor activity of CD8 \u00fe T lymphocytes via the AMPK-miR-107-eomes-PD-1 pathway","volume":"204","author":"Zhang","year":"2020","journal-title":"J Immunol"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2018-99-119665","article-title":"Predictors of T cell expansion and clinical responses following B-cell maturation antigen-specific chimeric antigen receptor T cell therapy (CART-BCMA) for relapsed\/refractory","volume":"132","author":"Cohen","year":"2018","journal-title":"Multiple Blood"},{"key":"R39-20230901","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"18950","DOI":"10.1038\/srep18950","article-title":"Design of chimeric antigen receptors with integrated controllable transient functions","volume":"6","author":"Juillerat","year":"2016","journal-title":"Sci Rep"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1002\/anie.201601902","article-title":"Design of switchable chimeric antigen receptor T cells targeting breast cancer","volume":"55","author":"Cao","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J Am Chem Soc"},{"key":"R45-20230901","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-20230901","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"R47-20230901","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R48-20230901","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-1-0716-0290-4_23","article-title":"Engineering T cells using CRISPR\/Cas9 for cancer therapy","volume":"2115","author":"Zhang","year":"2020","journal-title":"Methods Mol Biol"},{"key":"R49-20230901","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy","volume":"19","author":"Li","year":"2020","journal-title":"Brief Funct Genomics"},{"key":"R50-20230901","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2144\/btn-2019-0107","article-title":"Empowering chimeric antigen receptor T-cell therapy with CRISPR","volume":"68","author":"Zhou","year":"2020","journal-title":"Biotechniques"},{"key":"R51-20230901","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"K\u00f6hl","year":"2018","journal-title":"Hum Gene Ther"},{"key":"R52-20230901","first-page":"139","article-title":"Platforms for clinical-grade CAR-T cell expansion methods","volume":"2086","author":"Mizukami","year":"2020","journal-title":"Mol Biol"},{"key":"R53-20230901","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"R54-20230901","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"R55-20230901","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V126.23.684.684","article-title":"Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"issue":"(15_Suppl)","key":"R56-20230901","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/jco.2015.33.15_suppl.7010","article-title":"Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"R57-20230901","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R58-20230901","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/imt.15.6","article-title":"CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?","volume":"7","author":"Pegram","year":"2015","journal-title":"Immunotherapy"},{"key":"R59-20230901","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","volume":"171","author":"Evans","year":"2015","journal-title":"Br J Haematol"},{"key":"R60-20230901","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"R61-20230901","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R62-20230901","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"key":"R63-20230901","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"R64-20230901","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"R65-20230901","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00432-020-03198-7","article-title":"Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review","volume":"146","author":"Du","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"R66-20230901","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"R67-20230901","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R68-20230901","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"R69-20230901","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"R70-20230901","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2019-122724","article-title":"Phase 1\/2 study of AUTO3 the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 followed by an anti-PD1 in patients with relapsed\/refractory (r\/r) diffuse large B cell lymphoma (DLBCL): results of cohort 1 and 2 of the Alexander Study","volume":"134","author":"Ardeshna","year":"2019","journal-title":"Blood"},{"key":"R71-20230901","first-page":"4614","article-title":"Targeting primary pre-B cell acute lymphoblastic leukemia and CD19-negative relapses using trivalent CAR T cells","volume":"130","author":"Fousek","year":"2017","journal-title":"Blood"},{"key":"R72-20230901","first-page":"385","article-title":"Targeting two antigens associated with BALL with CD19-CD123 compound car T cell therapy stem","volume":"16","author":"Yan","year":"2020","journal-title":"Cell Rev Rep"},{"key":"R73-20230901","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"R74-20230901","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3324\/haematol.2011.049155","article-title":"The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-betaII depletion","volume":"97","author":"Biberacher","year":"2012","journal-title":"Haematologica"},{"key":"R75-20230901","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/1078-0432.CCR-19-3888","article-title":"Dissecting the tumor-immune landscape in chimeric antigen receptor T-cell therapy: key challenges and opportunities for a systems immunology","volume":"26","author":"Chen","year":"2020","journal-title":"Approach Clin Cancer Res"},{"key":"R76-20230901","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"},{"key":"R77-20230901","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R78-20230901","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-16-2138","article-title":"Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R79-20230901","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-16-1860","article-title":"Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting","volume":"23","author":"Slaney","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R80-20230901","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation. CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R81-20230901","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1200\/EDBK_200889","article-title":"CAR T cells and other cellular therapies for multiple myeloma: 2018 update","volume":"38","author":"Cohen","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R82-20230901","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Mackall tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"R83-20230901","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"key":"R84-20230901","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell nonhodgkin lymphoma","volume":"19","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"R85-20230901","first-page":"4415","article-title":"CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: a case report","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"R86-20230901","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","article-title":"Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma","volume":"55","author":"Hill","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R87-20230901","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell nonHodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"R88-20230901","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances antitumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R89-20230901","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/jcp.27519","article-title":"Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: a clinical perspective","volume":"234","author":"Mirzaei","year":"2019","journal-title":"J Cell Physiol"},{"key":"R90-20230901","first-page":"1","article-title":"Advanced cell mapping visualizations for single cell functional proteomics enabling patient stratification","volume":"20","author":"Bowman","year":"2020","journal-title":"Proteomics"},{"key":"R91-20230901","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-4939-9773-2_19","article-title":"Single-cell multiplexed proteomics on the isolight resolves cellular functional heterogeneity to reveal clinical responses of cancer patients to immunotherapies","volume":"2055","author":"Liu","year":"2020","journal-title":"Methods Mol Biol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:55:07Z","timestamp":1693551307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000671","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}